The Inaugural ISCT Clinical Applications Program for Fellows is a selective, ISCT-funded, in-person scholarship program. Delivered as an intensive two-day immersion, it equips clinical fellows with practical, clinic-facing skills to help advance cell and gene therapies (CGT) from bench to bedside.Led by world-class faculty from top-tier institutions, the program focuses on the highest-impact elements of clinical translation, including the pathway to first-in-human trials, ethical and regulatory considerations, trial design and site readiness, apheresis and infusion logistics, and management of complex toxicities. Scholars will also build a practical understanding of the clinical and manufacturing interface to partner effectively across CMC, operations, and external stakeholders.Designed for US and Canadian clinical fellows focused on advanced CGT clinical applications (e.g., hematology/oncology, transplantation, and immune-mediated diseases), this is a dedicated, peer-level environment built by leading CGT clinicians and scientists.
A fellows-only, peer-level environment built specifically for clinical fellows working in advanced CGT applications.
A concentrated two-day program focused on the highest-impact elements of translating CGT into real clinical practice. Practical and built for busy fellows.
Practical, end-to-end clinical translation and operations, including trial entry points, workflow and logistics, patient safety, and toxicity management, grounded in how CGT is actually delivered.
Course Content Learning Outcomes Designed For Eligibility Tuition & Funding
Upon completion of this program, scholars will be able to:
Draft agenda (subject to change). Sessions are designed as an intensive two-day immersion and will prioritize the most actionable clinical and operational learnings.
US and Canadian clinical fellows focused on advanced clinical applications of cell and gene therapy (CGT), such as hematology/oncology, transplantation, and immune-mediated diseases. A dedicated, peer-level environment designed by leading CGT clinicians and scientists, for clinical fellows.
To qualify for the program, applicants must:
Not applicable. This is a fully funded scholarship program.
If you have questions regarding the application process, please email workforcedevelopment@isctglobal.org.
Queenie Jang
Chief Executive OfficerISCT
“We aim to deliver meaningful, career-defining value to fellows on track to become leaders in the field, while also strengthening connections across the clinical CGT community through ISCT’s established global network.”
Miguel Forte
MD, PhD
PresidentISCT
“As a growing number of cell and gene therapies reach regulatory approval and move into routine clinical use, now is the critical moment to invest in clinicians who can lead their safe, effective, and equitable implementation for the benefit of patients.”
Dr. Alice Bertaina
Elected Member MDISCT Board of Directors
“By starting with fellows in specialties leveraging clinical cell and gene therapy methods, we are equipping future clinical leaders who can already make use of proven CGTs. We aim not only to prepare them to lead further use of these therapies in clinical practice, but also to be the first of a dedicated, global CGT-ready clinical community.”
Dr. Jaap Jan Boelens
ISCT Regional VP, North America
“We are bringing well-established CGT clinical practice to a specialized cohort of fellows. Future iterations will expand this model to additional clinical specialties, with each cohort joining a growing, global network of clinicians equipped to harness the full potential of cell and gene therapies for their patients.”
Become a sponsor of the ISCT Clinical Applications Program for Fellows and help provide full-tuition scholarships for a highly selective cohort of clinical fellows advancing cell and gene therapy (CGT) from bench to bedside. The program is strictly limited to 20 Scholars to ensure a high faculty-to-scholar ratio.
Your support helps strengthen the clinical pipeline by enabling fellows to build practical, clinic-facing skills in clinical translation, trial readiness, and the clinical–manufacturing interface.
ISCT maintains full independence over program content, faculty, and scholar selection.